Analyst Reco. Zealand Pharma A/S

Stocks

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-06-12 am EDT			5-day change	1st Jan Change
295.80 ^DKK	+0.51%		+17.24%	-36.58%

05:23am	After Euphoria, a Traffic Jam on the Multi-Billion Dollar Kilo-Highway
Jun. 11	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE

Analyst Reco.

Jun. 11	Wolfe Downgrades Zealand Pharma Following Weak Tolerability Data for Obesity Drug	FW
Jun. 10	DNB Carnegie trims Zealand Pharma price target to DKK 425 (440), reiterates Buy	FW
Jun. 03	Deutsche Bank raises Zealand Pharma price target to DKK 300 (275), reiterates Hold	FW
Jun. 01	BNP Paribas raises Zealand Pharma price target to DKK 350 (275), reiterates Neutral - BN	FW
May. 12	Barclays cuts Zealand Pharma price target to DKK 425 (560), reiterates Overweight - BN	FW
May. 08	Goldman Sachs trims Zealand Pharma price target to DKK 471 (491), reiterates Buy - BN	FW
May. 07	DNB Carnegie raises Zealand Pharma price target to DKK 440 (425), reiterates Buy	FW
Apr. 28	DNB Carnegie trims Zealand Pharma price target to DKK 425 (595), reiterates Buy	FW
Mar. 26	Wolfe Research Starts Zealand Pharma with Outperform Rating	MT
Mar. 26	Wolfe Research initiates coverage on Zealand Pharma with Outperform rating and DKK 750 price target - BN	FW
Mar. 20	Nykredit cuts Zealand Pharma price target to DKK 500 (650), reiterates Buy - BN	FW
Mar. 19	Danske Bank cuts Zealand Pharma price target to DKK 625 (770), reiterates Buy - BN	FW
Mar. 12	Deutsche Bank cuts Zealand Pharma price target to DKK 275 (450), reiterates Hold	FW
Mar. 11	JP Morgan lowers price target for Zealand Pharma to 460 Danish kroner (1,000), reiterates overweight - BN	FW
Mar. 09	BNP Paribas downgrades Zealand Pharma to neutral (outperform), price target 275 Danish kroner - BN	FW
Mar. 06	KBC Securities Downgrades Zealand Pharma to Accumulate, Cuts PT	MT
Mar. 06	Cantor Fitzgerald Downgrades Zealand Pharma to Neutral (Overweight) - BN	FW
Mar. 06	Zealand Pharma and Roche Report 10.7 Percent Weight Loss in Phase 2 Study (Update)	FW
Mar. 06	Nordea Downgrades Zealand Pharma to Hold (Buy)	FW
Feb. 20	UBS Lowers Price Target for Zealand Pharma to 700 Danish Kroner (760), Reiterates Buy	FW
Feb. 20	Goldman Sachs Raises Price Target for Zealand Pharma to 861 Danish Kroner (847), Reiterates Buy - BN	FW
Feb. 09	DNB Carnegie Lowers Price Target for Zealand Pharma to 595 Danish Kroner (610), Reiterates Buy	FW
Jan. 16	SEB Lists Nordic Favorites for Q1, Highlights a Swedish Quartet of Smaller Companies as Most Interesting	FW
Dec. 16	Deutsche Bank raises its target price for Zealand Pharma to DKK 450 (430), reiterates hold	FW
Dec. 08	JP Morgan Lowers Price Target for Zealand Pharma to 1,000 Danish Kroner, Reiterates Overweight Rating - BN	FW